drugset / Trial / NCT00087958
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.
Timeline
- Start
- 2004-08
- Primary completion
- 2007-02
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | larotaxel | Small molecule | — | Intravenous |